^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    c-MET inhibitor

    Related drugs:
    1d
    Savolitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors (clinicaltrials.gov)
    P1, N=41, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Apr 2026 --> Sep 2026
    Trial completion date
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET amplification • MET mutation
    |
    Orpathys (savolitinib)
    5d
    Large-scale transcriptomic data mining using explainable XGBoost and SHAP reveals shared biomarkers and molecular mechanisms between type-2 diabetes and triple-negative breast cancer for drug repurposing. (PubMed, BioData Min)
    Finally, we recommended sKGs-guided two repurposable common candidate drugs (tepotinib and ursodiol) for both diseases by molecular docking, ADME/T analysis and MD simulation studies. Thus, the results of this study could provide useful insights for researchers and medical professionals for improving the diagnostic and therapeutic strategies for the treatment TNBC with T2D as comorbidity.
    Journal
    |
    S100A9 (S100 Calcium Binding Protein A9) • PSMD1 (Proteasome 26S Subunit Non-ATPase 1)
    |
    Tepmetko (tepotinib)
    6d
    DUAL-THRUST: Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression (clinicaltrials.gov)
    P1/2, N=45, Recruiting, Second Affiliated Hospital of Nanchang University
    New P1/2 trial • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    Ivesa (firmonertinib) • vebreltinib (APL-101)
    8d
    EMB-01 in Combination With Chemotherapy for Unresectable or Metastatic Colorectal Cancer (clinicaltrials.gov)
    P1, N=120, Not yet recruiting, Shanghai EpimAb Biotherapeutics Co., Ltd.
    New P1 trial
    |
    5-fluorouracil • oxaliplatin • irinotecan • Lonsurf (trifluridine/tipiracil) • leucovorin calcium • bafisontamab (EMB-01)
    9d
    Efficacy and safety of first-line oral vinorelbine plus firmonertinib in refractory EGFR-mutated non-small cell lung cancer: study protocol of a multicenter, non-randomized, two-cohort study. (PubMed, Ther Adv Med Oncol)
    To the best of our knowledge, this study represents the first evaluation of vinorelbine plus firmonertinib in EGFR-mutated locally advanced or metastatic NSCLC with M1c2 disease or elevated PD-L1 expression, aiming to provide an effective, tolerable, and convenient all-oral treatment option for this refractory population. The study protocol (version 1.2; July 18, 2025) was registered on October 24, 2025, at the Chinese Clinical Trial Registry (ChiCTR2500111096).
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Rybrevant (amivantamab-vmjw) • Ivesa (firmonertinib) • Navelbine oral (vinorelbine tartrate oral)
    13d
    swalloWTail: A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=12, Completed, Janssen Research & Development, LLC | Active, not recruiting --> Completed
    Trial completion
    |
    docetaxel • Rybrevant (amivantamab-vmjw)
    14d
    SANOVO: Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC (clinicaltrials.gov)
    P3, N=412, Active, not recruiting, Hutchison Medipharma Limited | Trial completion date: Aug 2026 --> May 2028 | Trial primary completion date: Aug 2026 --> May 2028
    Trial completion date • Trial primary completion date
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET overexpression
    |
    Tagrisso (osimertinib) • Orpathys (savolitinib)
    19d
    A Study of PLB1001 in Non-small Cell Lung Cancer With c-Met Dysregulation(KUNPENG) (clinicaltrials.gov)
    P2, N=145, Completed, Beijing Pearl Biotechnology Limited Liability Company | Trial completion date: Dec 2025 --> Jun 2025 | Active, not recruiting --> Completed
    Trial completion • Trial completion date
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    vebreltinib (APL-101)
    21d
    Lung-MAP Sub-Study: Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial) (clinicaltrials.gov)
    P2, N=66, Recruiting, SWOG Cancer Research Network | Trial completion date: May 2027 --> Jun 2028 | Trial primary completion date: May 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • MET amplification
    |
    Tagrisso (osimertinib) • Cyramza (ramucirumab) • Tabrecta (capmatinib)
    22d
    SKIPPirr: Premedication to Reduce Amivantamab Associated Infusion Related Reactions (clinicaltrials.gov)
    P2, N=68, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Jul 2026 --> Mar 2027
    Trial completion date
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Tagrisso (osimertinib) • Rybrevant (amivantamab-vmjw) • dexamethasone • Lazcluze (lazertinib)
    22d
    A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=16, Recruiting, Memorial Sloan Kettering Cancer Center
    New P1 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • HER-2 mutation • EGFR T790M • MET exon 14 mutation • ALK fusion • ROS1 fusion • RET rearrangement
    |
    Tepmetko (tepotinib) • Idafang (ivonescimab)
    23d
    A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea (clinicaltrials.gov)
    P=N/A, N=44, Recruiting, Novartis Pharmaceuticals | N=250 --> 44
    Enrollment change
    |
    Tabrecta (capmatinib)